You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Selectin Inhibitor

Showing 51 - 75 of 7,510
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor Trial in Hangzhou (Vonoprazan Tablets, Amoxicillin Capsules,

Recruiting
  • Vonoprazan
  • +2 more
  • Vonoprazan Tablets
  • +2 more
  • Hangzhou, Zhejiang, China
    Hangzhou first people's Hospital
Nov 23, 2022

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)

Recruiting
  • Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 20, 2023

Delirium, Critical Illness, Sedation Complication Trial in Nashville (Dexmedetomidine, Midazolam)

Recruiting
  • Delirium
  • +4 more
  • Nashville, Tennessee
    Vanderbilt University Medical Center
Aug 21, 2022

Examining the Effect of Endocrine Therapy on Aging

Recruiting
  • Breast Neoplasm Female
  • +2 more
  • Aromatase inhibitor
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Jan 17, 2023

Healthy Male Trial in Shanghai (D-1553)

Active, not recruiting
  • Healthy Male
  • Shanghai, Shanghai, China
    Shanghai Xuhui District Central Hospital
Oct 23, 2023

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Aug 1, 2023

Hidradenitis Suppurativa Trial in Tampa, Baton Rouge (Placebo, Izokibep)

Recruiting
  • Hidradenitis Suppurativa
  • Tampa, Florida
  • +1 more
Jun 20, 2023

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Health Care Interventions and Outcomes of Major Bleedings in

Not yet recruiting
  • Major Bleeding
  • None (Observational study)
  • (no location specified)
Nov 17, 2023

Tumor, Solid, Pancreatic Cancer Trial in Chapel Hill (Ulixertinib, Palbociclib)

Recruiting
  • Tumor, Solid
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Nov 30, 2022

Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • B-Cell Lymphoproliferative Disorder
  • Boston, Massachusetts
  • +2 more
Feb 18, 2023

Toxic Epidermal Necrolysis Trial in Fuzhou (Abrocitinib)

Recruiting
  • Toxic Epidermal Necrolysis
  • Fuzhou, Fujian, China
    Department of Dermatology, the First Affiliated Hospital of Fuji
Oct 31, 2023

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

Non Small Cell Lung Cancer, KRAS Activating Mutation Trial in United States (VS-6766 and sotorasib)

Recruiting
  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation
  • avutometinib (VS-6766) and sotorasib
  • Washington, District of Columbia
  • +6 more
Jan 31, 2023

Determine Pro-Inflammatory Cytokine Kinetics During Immune

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Melanoma
    • Indianapolis, Indiana
      Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
    Jan 30, 2023

    Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial in Worldwide (BCX9930, Eculizumab, Ravulizumab)

    Active, not recruiting
    • Paroxysmal Nocturnal Hemoglobinuria (PNH)
    • Paris, France
    • +6 more
    Dec 15, 2022

    NSCLC Trial in Worldwide (Tepotinib, Osimertinib)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Yuma, Arizona
    • +178 more
    Dec 19, 2022

    Depressive Disorder, Major Trial in Worldwide (Esketamine, SSRI/SNRI)

    Active, not recruiting
    • Depressive Disorder, Major
    • Ciudad Autonoma de Buenos Aires, Argentina
    • +58 more
    Jan 31, 2023

    Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)

    Active, not recruiting
    • Breast Cancer
    • Guangzhou, Guangdong, China
      State Key Laboratory of Oncology in South China, Sun Yat-sen Uni
    Jan 27, 2023

    Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

    Completed
    • Advanced Solid Tumor
    • Inosine 0.2g orally 3 times/day
    • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
    • Beijing, Beijing, China
      Qin li
    Mar 30, 2023

    NSCLC Trial in Worldwide (JTX-4014, Vopratelimab)

    Active, not recruiting
    • NSCLC
    • Minsk, Belarus
    • +70 more
    Jan 18, 2023

    Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or

    Recruiting
    • Ovarian Cancer
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Jul 13, 2022

      Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma Trial in Worldwide (INCB086550)

      Active, not recruiting
      • Non Small Cell Lung Cancer
      • +4 more
      • Burgas, Bulgaria
      • +19 more
      Oct 20, 2022